Chronic Stable Angina
TA Sciences Presentation
19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.
Bioabsorbable Drug-Eluting Cardiac Stent Analysis
B. C. Kansupada, MD, HeartCare Assoc. ACC chapter talk 4/28/06
Effect of Glucagon-Like Peptide-I (GLP-I) Analogue in ...
Europcr2014 1.10
Holistik papdi by prof dr.jose rosma
Metabolic syndrome is a key determinant of microvascular function
InTech-Ivabradine Versus Beta Blockers in Patients With Conduction Abnormalities or Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Grafting
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):1943-1950.
Effect of Glucagon-Like Peptide-I (GLP- I) Analogue in Patients with Stable Coronary Artery Disease With Left Ventricular Ejection Fraction ≤ 40 %. Principal.
